| DC10743 |
ml335
Featured
|
ML335 is a selective activator of both TREK-1 and TREK-2. |
|
| DC7797 |
ML365
Featured
|
ML365 is a novel selective small molecule inhibitor of TASK1(KCNK3) with IC50 of 4 nM(thallium influx fluorescent assay) and 16 nM(automated electrophysiology assay). |
|
| DC10557 |
ML402
Featured
|
ML402 is a selective TREK-1 activator. |
|
| DC8969 |
Nicorandil |
Nicorandil is potassium channel activator. |
|
| DC9131 |
Nimodipine |
Nimodipine(Nimotop) is a dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity.Nimodipine decreases intracellular free Ca2+,Beclin-1 and autophagy. |
|
| DC8789 |
NS 11021
Featured
|
NS 11021 is an activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1). |
|
| DC9734 |
NS-1619
Featured
|
NS-1619 is a selective MaxiKα (large conductance calcium activated potassium channel) activator. |
|
| DC6910 |
NS-1643
Featured
|
NS1643 is a potent human ether-a-go-go related gene (hERG) KV11.1 channel activator (EC50 = 10.5 μM). |
|
| DC7833 |
NS309
Featured
|
NS309 is a positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels); increases Ca2+ sensitivity. Displays no activity at BK channels. |
|
| DC8269 |
NS6180
Featured
|
NS6180 is a novel inhibitor of the intermediate-conductance Ca2+-activated K+ channel (KCa3.1) |
|
| DC12096 |
Pinacidil monohydrate (Pinacidil hydrate)
Featured
|
Pinacidil monohydrate, an antihypertensive drug, is a potassium channel activator. |
|
| DC8807 |
Retigabine dihydrochloride
Featured
|
Retigabine 2Hcl (Ezogabine; D23129) is a Kv7.2-7.5 (KCNQ2-5) neuronal potassium channel opener witrh anticonvulsant activity. |
|
| DC8105 |
RPR-260243 |
RPR260243 was the first reported hERG channel activator. |
|
| DC9600 |
Senicapoc
Featured
|
Senicapoc(ICA17043) is a potent and selective Gardos channel blocker; blocked Ca(2+)-induced rubidium flux from human RBCs/ inhibited RBC dehydration with IC50s of 11 nM/30 nM, respectively.
IC50 value: 11/30 nM [1]
Target: Gardos channel
in vitro: I |
|
| DC11376 |
SKA-121
Featured
|
SKA-121 is a positive-gating modulator of intermediate-conductance calcium-activated potassium channels (IKCa1/KCa3.1) with an EC50 value of 109 nM using whole-cell patch-clamp electrophysiology with calcium in the internal solution. |
|
| DC11947 |
ML418
Featured
|
The first potent, selective, CNS penetrating inward rectifier potassium channel Kir7.1 (KCNJ13) inhibitor with IC50 of 0.31 uM. |
|
| DC11940 |
VU590 |
The first small-molecule inhibitor of renal outer medullary potassium channel (ROMK, Kir1.1) and Kir7.1 with IC50 of 294 nM for ROMK. |
|
| DC11357 |
Tolazamide |
Tolazamide is a first generation sulfonylurea that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (KIR6.2; IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). |
|
| DC9023 |
Tolbutamide |
Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug. |
|
| DC9598 |
TRAM-34
Featured
|
TRAM-34 is a highly selective blocker of intermediate conductance Ca2+-activated K+ channels (KCa3.1) (Kd = 20 nM). |
|
| DC9094 |
Ropivacaine mesylate |
|
|
| DC9066 |
Quinidine |
|
|
| DC11941 |
VU590 dihydrochloride |
|
|
| DC11945 |
VU714 oxalate |
|
|
| DC28081 |
Dofetilide N-oxide |
Dofetilide N-oxide (UK-116856) is a metabolite of Dofetilide. Dofetilide is a class III antiarrhythmic agent that blocks potassium channels. |
|
| DC28086 |
4-Hydroxytolbutamide |
4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic. |
|
| DC28263 |
NS8593 hydrochloride
Featured
|
NS8593 hydrochloride is a potent and selective small conductance Ca2+-activated K+ channels (SK channels) inhibitor. NS8593 hydrochloride reversibly inhibits SK3-mediated currents with a Kd value of 77 nM. NS8593 hydrochloride inhibits all the SK1-3 subtypes Ca2+-dependently (Kds of 0.42, 0.60, and 0.73 μM, respectively, at 0.5 μM Ca2+), and does not affect the Ca2+-activated K+ channels of intermediate and large conductance (hIK and hBK channels, respectively). |
|
| DC28311 |
A-935142 |
A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization. |
|
| DC28389 |
VU041 |
VU041 is a first submicromolar-affinity inhibitor of Anopheles (An.) gambiae and Aedes (Ae.) aegypti inward rectifier potassium 1 (Kir1) channels with IC50 values of 2.5 μM and 1.7 μM, respectively. VU041 inhibits appreciably is mammalian Kir2.1 (IC50 of 12.7 μM), and has less inhibitory effect on mammalian Kir1.1, Kir4.1, Kir6.2/SUR1, and Kir7.1. VU041 also induces impaired Malpighian tubule function. |
|
| DC28398 |
Tifenazoxide |
Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective KATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis. |
|
